TNFA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TNFA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
TNF Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.01 Mil. TNF Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. TNF Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2024 was $-8.76 Mil. TNF Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.00.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for TNF Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
The historical data trend for TNF Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNF Pharmaceuticals Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Debt-to-EBITDA | -0.50 | -0.01 | -0.01 | - | - |
TNF Pharmaceuticals Quarterly Data | |||||||||||||||||||
Mar20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, TNF Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TNF Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TNF Pharmaceuticals's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
TNF Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.011 | + | 0) | / | -8.66 | |
= | -0.00 |
TNF Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.011 | + | 0) | / | -8.756 | |
= | -0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.
TNF Pharmaceuticals (NAS:TNFA) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of TNF Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Rivard | officer: EVP of Operations, GC | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Caroline C Williams | 10 percent owner | 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
Adam Kaplin | officer: Chief Scientific Officer | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Jude Uzonwanne | director | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Craig Eagle | director | POST OFFICE BOX 4590, NEW YORK NY 10163 |
Chapman Christopher C Jr | director, officer: President, Chief Med. Officer | C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814 |
Ian Rhodes | officer: Interim CFO | 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824 |
Stuart M Benson | officer: Chief Financial Officer | EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118 |
Hudson Bay Capital Management Lp | 10 percent owner | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Sander Gerber | 10 percent owner | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Robert C Schroeder | director | 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724 |
Howard Yeaton | officer: CEO, CFO | 79 LLOYD ROAD, HOHOKUS NJ 07423 |
Tarbox Richard C Iii | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
Christopher C Schreiber | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
From GuruFocus
By Business Wire • 10-19-2023
By Business Wire • 02-13-2024
By Business Wire • 01-29-2025
By GuruFocus Research • 02-08-2024
By Business Wire • 10-02-2024
By GuruFocus Research • 02-08-2024
By Business Wire • 12-06-2023
By Business Wire • 01-15-2025
By GuruFocus News • 04-22-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.